Previous close | 0.0018 |
Open | 0.0018 |
Bid | 0.0018 x 0 |
Ask | 0.0020 x 0 |
Day's range | 0.0017 - 0.0019 |
52-week range | 0.0014 - 0.0602 |
Volume | |
Avg. volume | 12,226,579 |
Market cap | 6.376M |
Beta (5Y monthly) | 1.06 |
PE ratio (TTM) | N/A |
EPS (TTM) | -5.0000 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
BAYTOWN, TX, July 25, 2024 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp (Expert Market: SAGA) (the “Company”) announced today that it believes that a misleading press release has been issued by Nika Pharmaceuticals, Inc. in another attempt by NIKA and its CEO, Dimtar Savov, to falsely claim rights to patents issued to Harry H. Zhabilov and the Zhabilov Trust for the Immunotherapy treatment of HIV/AIDS. Mr. Savov has erroneously and maliciously asserted claims to ITV-1 in attempts to mislead the
Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/"https://enzolytics.com/). Enzolytics, Inc. (the "Company") On March 19th, 2024, a Special Meeting of the Shareholders of ENZC of which a quorum was present representing over 51% of the voting right of the company was held and new board of directors was elected.